Posted by Michael Wonder on 28 Jun 2017
ICER evidence report on abuse deterrent opioids finds limited evidence to demonstrate real world impact on opioid abuse
28 June 2017 - With substantially higher costs for abuse-deterrent formulations, and uncertainty regarding their impact on abuse, diversion, and switching to other opioids, ICER economic analysis highlights difficulty in assessing societal impact and value of shifting patients to abuse-deterrent opioids.
The Institute for Clinical and Economic Review (ICER) has released an Evidence Report assessing the comparative clinical effectiveness and value of 10 abuse-deterrent formulations (ADFs) of opioids.
The report finds that current evidence is limited to judge the potential of ADFs to effectively reduce abuse on a widespread basis, and that their use generates significant costs, even after accounting for possible reductions in abuse.
